Ipsen’s state-of-the-art R&D center is located in Cambridge, one of the world’s most vibrant biomedical science and biotechnology hubs, with the exceptional environment of universities and academic institutions, prestigious hospitals and major players in pharmaceuticals, biotechnologies and start-ups including some Ipsen’s partners. In other words, Ipsen wants to be at the heart of biological revolution currently underway and to partner with pioneers that drive it.
This meeting and the outstanding caliber of the chairs and speakers represent a true testimony of Ipsen’s longstanding commitment to science and innovation and a dedication to bringing together the very best minds in the world of academia to transform knowledge into novel and differentiated medicines for patients in needs.
Ipsen has established its first R&D center in the US in 1976, with the ambition of becoming a global leader in peptide drug discovery and formulation. In Cambridge,
Ipsen will dedicate its resources to combine the Group’s peptide and toxin expertise and knowledge to introduce new therapeutic solutions for debilitating diseases.
Opening : Claude BERTRAND (Ipsen Pharma, Executive Vice President, Research & Development, Chief Scientific Officer).
Chair: Robert WEINBERG (Massachusetts Institute of Technology, Cambridge, MA)
Closing Remarks : Marc de GARIDEL (Ipsen Pharma, Chairman & CEO, Paris)
From left to right: David Edwards, the founder of Le Laboratoire, a contemporary art and design center ; Claude Bertrand, Executive Vice President, R&D, Chief Scientific Director ; Philip Sharp, Nobel Prize ; Leslie Sloan, President, Ipsen Bioscience, VP, Global R&D Project management & analytics ; Marc de Garidel, Chairman and Chief Executive Officer ; J. Michael Bishop, Nobel Prize ; Robert Weinberg, MIT ; Antonio Damasio, USC College Brain and Creativity Institute ; Fred Gage, Salk Institute for Biological Studies.